Hartland wrote: "Bear is this presentation likely to be new info or a reiteration of the last one.I must say it was hard for me to understand the charts the last time.In previous presentation  the charts were pretty clear.Who had progression  and who was still ok.The last understanding  was the 3 at about 40 odd weeks are they still ok?We may hear how they are funding the expanded trial."

I sure hope that we hear something new at the BIO International presentation June 4th 2:30 to 2:45 EST. Back in the March BIO-Europe presentation, they stated "Several patients with primary Abiraterone resistance remain on study > 46 weeks." So those patients are over a year now, if still going. Status of current trial? Plans for other cancer trials? Financing/deals/partnerships? Publications? Lots of questions that they could provide clarity on. Whether they will is another question.

BearDownAZ